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Intravenous immunoglobulin protects against experimental ized by the presence of endothelial cell injury, glomerular
thrombotic microangiopathy. capillary thrombosis, and widening of the subendothelial
Background. Intravenous immunoglobulin (IVIG) has been space, often in association with thrombocytopenia, hemo-utilized in several forms of vasculitis and has many potential
lytic anemia, and fragmented erythrocytes. The conditionmechanisms of action, including the inhibition of C3 activation.
has a number of different etiologies, including idiopathic,We have previously demonstrated that IVIG can reduce glo-
merular injury in a model of membranous nephropathy medi- hemolytic uremic syndrome, thrombotic thrombocyto-
ated by C5b-9 [1]. C5b-9 has also been shown to mediate the penic purpura, connective tissue diseases, drugs, radia-
thrombotic microangiopathy (TMA) induced by antibody to tion, pregnancy, and malignant hypertension.
glomerular endothelial cells leading to a hemolytic uremic syn-
We have developed a model of TMA in uninephrec-drome-type lesion [2].
tomized rats in which perfusion of the right renal arteryMethods. To test the hypothesis that IVIG might be effective
in treating antibody-induced TMA, male uninephrectomized with an antibody to glomerular endothelial cells (anti-GEN
rats underwent right renal artery perfusion with goat anti-rat antibody) leads to the development of acute renal failure
glomerular endothelial cell (GEN) antibody (20 mg/kg). Sheep associated with thrombocytopenia and anemia with schis-
IgG (200 mg/kg) was administered either 30 minutes before the
tocytes [3]. Renal injury occurs rapidly in this model andrenal artery perfusion (group I, N 6) or 30 minutes postperfu-
is characterized by endothelial cell injury, platelet aggre-sion (group II, N  9). A third control group received phos-
gation, fibrin deposition, and acute tubular injury. Thephate-buffered saline (PBS; group III, N  12). A survival
biopsy was performed at 15 minutes, and the animals were sacri- injury is complement dependent and mediated by the
ficed on day 2. terminal complement complex C5b-9. Strategies that in-
Results. There were no significant differences in proteinuria hibit complement action have been shown to reduce injuryor hematocrit between the groups. Animals pretreated with IVIG
in this model. Complement depletion with cobra venomhad significantly improved survival and renal function, which
factor prevents the disease, and C6-deficient rats thatwas associated with a decrease in glomerular C3 deposition.
The protective effect of IVIG was abolished if the administra- are unable to form C5b-9 are similarly protected from
tion was delayed 30 minutes after perfusion. injury [2]. In contrast, inhibition of the action of comple-
Conclusions. IVIG is effective in reducing injury in experi- ment regulatory proteins can potentiate injury [4].mental TMA only if given prophylactically. The effect is medi-
Intravenous immunoglobulin (IVIG) is known to haveated by inhibition of local intraglomerular complement activation.
a number of immunosuppressive and anti-inflammatory
effects and has been used in a wide range of human auto-
immune diseases, including Wegener’s granulomatosis,Thrombotic microangiopathy (TMA) is an increasingly
Kawasaki disease, idiopathic thrombocytopenic purpura,recognized cause of acute renal failure and is character-
Guillain-Barre syndrome, and dermatomyositis. Several
mechanisms of action for IVIG have been postulated,
1 Current location: Belfast City Hospital, Belfast, Northern Ireland. including the blockade of Fc receptors on cells of the
2 Current location: Baylor College of Medicine, Houston, Texas, USA. reticuloendothelial system [5, 6], anti-idiotype binding
of autoantibodies [7], modulation of cytokine productionKey words: complement, hemolytic uremic syndrome, glomerular en-
dothelial cell, capillary thrombosis, kidney injury. by lymphocytes [8], enhancing catabolism of pathogenic
autoantibodies [9], and inhibition of complement activa-Received for publication June 14, 2000
tion [10–12].and in revised form April 3, 2001
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phropathy mediated by C5b-9 [1]. In our current study, Quantitative immunofluorescence densitometry. Quan-
titative immunofluorescence densitometry was performedwe hypothesized that IVIG may inhibit complement acti-
to quantify the amount of goat IgG, sheep IgG, and C3vation and protect against antibody-induced TMA.
deposition in the glomeruli. This was performed on a
Leitz immunofluorescence microscope with visual output
METHODS connected to a photomultiplier as described previously
Disease model [14]. Briefly, all densitometry readings were done at630,
and the size of the densitometry field was fixed such thatMale Sprague-Dawley rats weighing 250 to 300 g
an average glomerular cross-section exceeded the field(Charles River Breeding Laboratories, Wilmington, MA,
by 10 to 20%. Whole glomeruli that completely filledUSA) were allowed free access to standard rat chow and
the defined field were identified by light microscopy scan-water and were housed in an accredited animal facility.
ning. Twenty separate glomeruli were read in every sec-The animals were anesthetized with ketamine and under-
tion, and glomerular fluorescence for a section was thenwent left uninephrectomy followed by selective right re-
calculated as a mean of these readings. All tissues werenal artery perfusion with purified IgG fraction of goat
cut, stained, and analyzed in a single setting to minimizeanti-GEN antibody as previously described [3]. Ischemia
effects due to tissue processing or intensity of the ultravi-time was less than six minutes. A survival cortical biopsy
olet light source. Results are expressed as relative fluo-was performed in each animal at 15 minutes to assess
rescence units (RFUs) equal to the reciprocal of theantibody binding.
exposure time.
Purification of sheep IgG. Sheep plasma was pur-Experimental protocol
chased from Triple J Farms (Bellingham, WA, USA). IgGThree groups of rats were employed. All animals un-
was purified using a caprylic acid precipitation methodderwent right renal artery perfusion with 20 mg/kg anti-
[15]. After adjusting the pH of the plasma to 5.5 withGEN antibody. Group I (N  12) received control PBS
HCl, 5.5 mL/100 mL plasma of caprylic acid solution30 minutes before renal artery perfusion. Group II (N
(Sigma, St. Louis, MO, USA) was added dropwise with6) received IVIG (200 mg/kg in control PBS) 30 minutes
vigorous stirring. The solution was stirred at room tem-before renal artery perfusion. Group III (N 9) received
perature for one hour and centrifuged at 14,000 rpm forIVIG (200 mg/kg in PBS) 30 minutes after the renal
30 minutes at 4C. The supernatant was collected andartery perfusion. Blood samples for hematocrit, serum
dialyzed against PBS. The dialyzed solution was centri-complement C3, serum CH50, and blood urea nitrogen fuged at 14,000 rpm for 30 minutes at 4C. The superna-(BUN) were collected from the tail vein at time zero,
tant was sterilized by filtration and stored at 4C. The IgG
and at 24 and 48 hours. A 12-hour urine collection was solution was concentrated utilizing centriplus (Amicon,
done on postoperative day 1, and the animals were sacri- Beverly, MA, USA) to a final concentration of 40 mg/mL.
ficed on day 2. Renal tissue was collected in methylcar- Serum complement C3 and CH50. Serum C3 was mea-noy’s fixative and snap frozen in liquid nitrogen for his- sured at 24-hours postinfusion by radial immunodiffu-
tology. sion. Briefly, 1.5% agarose in 0.5 mol/L veronal buffer
Histopathology. Renal tissue was fixed in methylcar- containing a 1:50 dilution of goat anti-rat C3 IgG (Cap-
noy’s, embedded in paraffin blocks, and cut into 4 m pel, Durham, NC, USA) was poured, and after cooling,
sections. Tissue was stained with periodic acid-Schiff (PAS) 2 mm holes were punched. Then 3 L samples of rat C3
for morphology and with RECA-1, a monoclonal anti- standards as well as 3 L of rat plasma were added. The
body specific for rat endothelial cells to assess endothe- diameters of the rings from precipitation of rat C3 in
lial integrity [13]. the plasma samples by the antibody were read of the
Tissue for immunofluorescence was embedded in OCT, curve generated by the diameters of the rings of the
snap frozen in liquid nitrogen cooled isopentane, and known standards. CH50 was measured by the hemolysis
stored at 70C until processed. Four-micron sections of sheep erythrocytes sensitized by specific antibodies
were cut and fixed with 1:1 ethanol/ether. Sections were (anti-sheep hemolysin) and compared with serum from
stained with FITC-conjugated goat anti-rat C3, which the rats on day 0. The degree of hemolysis is expressed
reacts primarily with rat C3c [14], rabbit anti-goat IgG, as CH50 units. One CH50 unit is defined as the volume
and rabbit anti-sheep IgG (Cappel, Durham, NC, USA). of serum that will lyse 50% of the erythrocytes in the
Tubulointerstitial injury score. Tubulointerstitial in- reaction mixture. The number of CH50 units in 1 mL of
jury was scored according to the presence of tubular serum is the hemolytic titer. Results of serum C3 and
hypercellularity, cell sloughing, basement membrane CH50 are expressed as the percentage of baseline value.
thickening, tubular dilation, or tubular atrophy on a scale
Miscellaneousof 1 to 4 determined by the percentage area of tubulo-
interstitium affected (0 to 25% score 1; 26 to 50% score Blood urea nitrogen was determined colorimetrically
using a commercial kit for the measurement of urea2; 51 to 75% score 3; and 76 to 100% score 4).
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Fig. 1. Equivalent binding of goat IgG in a capillary wall distribution between the three groups (A) control, (B) IVIG-pre, (C) IVIG-post;
immunofluorescence 100. (D) Comparison of three groups.
nitrogen (Sigma Diagnostics). Urine protein excretion ing to the goat anti-GEN antibody following tissue local-
was measured by sulfosalicylic acid method. ization in the glomerulus.
Statistics Survival data
All scores for immunohistochemical staining were Intravenous immunoglobulin given preperfusion sig-
done by a single blinded observer. All results are ex- nificantly improved survival in this model [7 out of 12
pressed as mean SD. Analysis was performed by analy- survived (control) vs. 6 out of 6 (IVIG-pre, P  0.009)
sis of variance with an individual group comparison made vs. 5 out of 9 (IVIG-post)]. The experimental mortality
by the Student t test with Bonferonni correction. in the control group was higher than previously seen
with this model. All animal deaths occurred between
4 and 20 hours postsurgery, and autopsy examination
RESULTS revealed no evidence of hemorrhage or infection. Of
Anti-GEN antibody deposition note, a more potent batch of anti-GEN antibody was
used in this experiment than in previous experiments;All rats perfused with anti-GEN IgG exhibited diffuse
however, the exact cause of death was unclear. Remark-glomerular staining for goat IgG along all capillary walls
ably, IVIG given preperfusion resulted in 100% survival.in a coarse uninterrupted pattern (Fig. 1). To determine
whether IVIG interfered with the binding of anti-GEN
Functional dataantibody to target cells, quantitative immunofluores-
There was no significant difference in proteinuria orcence was performed. There was no difference in mean
hematocrit between the three groups (Table 1). Assess-antibody binding between the three groups [0.016 
ment of renal function by BUN revealed a significant0.003 RFU (control) vs. 0.019  0.005 (IVIG-pre) vs.
protective effect of giving IVIG preperfusion compared0.018  0.003 (IVIG-post), F  1.4, P  0.24; Fig. 1].
Staining for sheep IgG was negative, indicating no bind- with control (mean BUN 43.6  12.0 vs. 77.0  20.8
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Table 1. Results
IVIG
Control Pre Post
Hematocrit % 37.81.7 411.4 38.71.2
Urine protein mg/day 21.62.4 24.12.1 19.42.9
BUN mg/dL 779.3 43.64.9a 66.66.8
Serum C3 mg/dL 82.32.6 87.51.5 84.46.2
CH50 % 74.43.1 76.23.6 71.09.8
TI score (1- 4) 2.80.7 0.170.17a 2.58.7
Abbreviations are: IVIG, intravenous immunoglobulin; BUN, blood urea
nitrogen; CH50, total hemolytic complement activity; TI, tubulointerstitial injury.
a P  0.01, statistically significant versus control group
Fig. 2. Intravenous immunoglobulin (IVIG) given preperfusion pro-
tects renal function at 48 hours (**P  0.01).
mg/dL, P 0.009). This protective effect was lost if IVIG
was delayed and given 30-minutes postperfusion (66.6 
13.6 vs. 77.0  20.8 mg/dL, P  0.41; Fig. 2).
thrombocytopenia, and fragmented red blood cells. En-
Renal histology dothelial cell injury, which is thought to be central to
Periodic acid-Schiff staining revealed marked glomer- the pathogenesis of this disorder, may lead to cell death
ular injury with capillary thrombosis in the control group or endothelial cell activation with the expression of von
and IVIG-post groups (Fig. 3). This was accompanied Willebrand factors (vWF) promoting platelet aggrega-
by a loss of RECA-1 staining indicating glomerular endo- tion. The subsequent platelet thrombi lead to mechanical
thelial cell loss. The IVIG-pre group revealed only minor injury to red cells and occlusion of small vessels, resulting
glomerular abnormalities in scattered glomeruli with in downstream ischemic injury. Recent evidence has im-
preservation of endothelial integrity. plicated a failure of metabolism of unusually large vWF
There also was marked tubulointerstitial injury in the multimers in thrombotic thrombocytopenic purpura by
control and IVIG-post groups as evidenced by tubular a cleaving protease, which is inhibited by an autoanti-
dilation, tubular cast formation, and tubular cell sloughing. body in the nonfamilial form of this disease [16, 17].
The IVIG-pre group showed minimal injury (Fig. 4). We have developed a model of TMA induced by the
Mean tubulointerstitial score was significantly less for direct intra-arterial infusion of antiglomerular endothe-
the IVIG-pre group [2.8  1.6 (control) vs. 0.17  0.4 lial cell antibody (AECA) into the right kidney. Endo-
(IVIG-pre, P  0.004) vs. 2.5  1.7 (IVIG-post)]. thelial cell injury occurs rapidly, resulting in platelet
thrombi and glomerular capillary thrombosis. Acute tu-Serum C3 level and CH50
bular injury is a prominent feature in this model as a
To determine that the reduction in glomerular C3 downstream consequence of glomerular microvascular
binding was not due to systemic complement depletion, thrombosis. The injury is mediated by complement and
serum C3 levels and CH50 were measured. There was no the membrane attack complex C5b-9. Systemic comple-
significant difference between the groups in serum C3 ment depletion with cobra venom factor abolishes the
levels [82.4%  5.9 (control) vs. 87.6%  3.6 (IVIG-pre)
renal injury, and because C6-deficient PVG rats with
vs. 84.4%  10.7 (IVIG-post)] or serum CH50 [74.4%  that depletion are unable to form C5b-9, they are pro-6.8 (control) vs. 76.2  8.8 (IVIG-pre) vs. 71.0  19.5
tected from injury [2]. In contrast, inhibiting the action(IVIG-post); P  0.10].
of CD59, a cell-bound inhibitor of C5b-9 formation, en-
hances renal injury [4]. This is in contrast to the Con AGlomerular C3 deposition
anti-Con A model of glomerular endothelial injury, whichGlomerular binding of C3 was assessed by quantitative
is complement dependent, but mediated primarily byimmunofluorescence at 15 minutes. There was a significant
neutrophils and not C5b-9 [18].reduction in glomerular C3 binding in group II animals
In this model, antibody binding to the endotheliumpretreated with IVIG compared with control [0.013 
leads to rapid complement activation and apoptotic in-0.003 RFU (control) vs. 0.009  0.002 (IVIG-pre, P 
jury to the endothelium [19]. C5b-9 also may cause endo-0.01) vs. 0.015  0.003 (IVIG-post, P  0.25); Fig. 5].
thelial cell activation. In vitro studies have shown C5b-9
to promote a procoagulant phenotype with increased
DISCUSSION expression of high molecular weight vWF multimers [20],
increased tissue factor expression [21], and loss of endo-Thrombotic microangiopathy is an important cause
of acute renal failure that is characterized by anemia, thelial cell layer integrity [22].
Jefferson et al: IVIG protects against experimental TMA1022
Fig. 3. Severe glomerular injury with capil-
lary thrombosis in control group (A) associ-
ated with loss of RECA-1 staining reflecting
glomerular endothelial cell loss (B). This is
markedly improved by IVIG preperfusion (C
and D). The protective effect is lost if IVIG
is delayed by 30 minutes (E and F; 100).
This study demonstrates that IVIG, when adminis- and reduce the formation of membrane attack complex
C5b-9. Others have suggested that IVIG enhances thetered before perfusion with anti-GEN antibody, mark-
edly reduced the renal injury. An improvement in sur- physiological inactivation of C3b by factor H and factor
I [11], or that the binding of C1q by sites on the Fcvival was also found, although it should be noted that
the experimental mortality in the control groups in this portion of the immunoglobulin molecule may account
for the complement inhibitory effect [12]. In vivo, IVIGstudy was higher that we have previously found with
this model. Although a more potent batch of anti-GEN has been shown to be protective in complement-medi-
ated experimental models of membranous glomerulo-antibody was used in this experiment, the exact cause
of the higher mortality was unclear. The protective effect nephritis [1], hyperimmune xenograft rejection [26], the
anti–Thy-1 model of mesangial proliferative glomerulo-of IVIG was lost if the administration was delayed 30-
minutes postperfusion. nephritis [27], and the Forsmann shock model [28].
Intravenous immunoglobulin, particularly in its poly-The most likely mechanism of action would be inhibi-
tion of the binding of anti-endothelial cell antibody to meric form, also may cause systemic complement deple-
tion. In this study, there was no difference in serum C3endothelial cells by IVIG, and this has previously been
described in vitro [23]. However, in this model, equiva- levels or CH50 between the groups. The reduction in renal
injury was associated with a decrease in glomerular stain-lent binding of goat anti-GEN antibody was demon-
strated by quantitative immunofluorescence densitome- ing for C3, suggesting that IVIG may be acting by inhib-
iting local complement activation. Reduced C3 bindingtry in all three groups. IVIG has also been shown to
inhibit complement activation. IVIG may act as a scaven- would interfere with the assembly of C5b-9 due to the
unavailability of C3b for incorporation into the enzymeger for activated complement components C3b and C4b
diverting activated complement components from the C5 convertase required for the production of C5b-9.
The lack of a protective effect of IVIG given 30 min-target cell [10, 24, 25]. This could limit the availability
of C3b molecules for incorporation into C5 convertase utes after disease induction reflects the rapid course of
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Fig. 4. Marked tubulointerstitial injury with tubular dilation and tubular cast formation. (A) control, (B) pre-IVIG, (C) IVIG postperfusion; PAS
strain 40. The mean tubulointerstitial score is significantly reduced in group given IVIG preperfusion (B). (D) **P  0.01.
injury in this single-hit model. Complement-mediated jury involves antibody, there is recent evidence sug-
gesting that complement may have a role in the endothe-injury occurs very rapidly, and there is evidence of in-
creased apoptosis and loss of endothelial integrity within lial injury in human TMA and HUS. Low serum C3
levels are described in both familial HUS [34, 35] andthe first hour [19]. In contrast, human disease is charac-
terized by ongoing endothelial cell insults, and IVIG during the acute phase of sporadic HUS [36–38], and
granular C3 deposits have been described in the glomer-may have a role in inhibiting persistent complement acti-
vation. uli and arterioles of HUS renal biopsies [36, 39, 40]. In
some families with HUS, an impaired inhibitory function
Relevance of findings to human disease of factor H, a complement regulatory protein of the
alternate pathway, has been reported [41], and moreHow does one equate the current findings to human
disease? Most cases of hemolytic uremic syndrome (HUS) recently, mutations in the factor H gene have been de-
scribed [42].are associated with E. coli infection in which it is thought
that the endothelial cell injury is mediated by binding The observation that IVIG in our model could block
local complement-mediated injury to glomerular endo-of verotoxin to the Gb3 receptor on renal microvascular
endothelial cells [29]. Unfortunately, rodents do not ex- thelial cells may thus be relevant to some forms of human
HUS. That the IVIG therapy was only protective whenpress this receptor in the kidney, and hence, animal mod-
els of HUS/TTP have been difficult to develop. Our administered prophylactically does not necessarily ne-
gate its benefit in human disease, as in our model, themodel is induced by an antibody to glomerular endothe-
lial cells; however, there is controversy over the role of injury is induced as a one-time hit by anti-GEN antibody,
whereas in human disease the injury is presumably medi-AECAs in the pathogenesis of human disease character-
ized by endothelial injury [30–33]. ated either by a circulating toxin or autoantibody, and
hence the endothelial insult is ongoing. Indeed, IVIG hasRegardless of whether the initiating mechanism of in-
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Fig. 5. Glomerular binding of C3 (A-C) is significantly reduced in group pretreated with IVIG (B). (D) **P  0.01; immunofluorescence 100.
Reprint requests to J. Ashley Jefferson M.D., Regional Nephrologybeen used in cases of TMA [43]. One report described the
Unit, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, Northerninefficacy of IVIG in HUS [44]; however, many of these Ireland.
cases had features typical of TTP and would have likely E-mail: ashley.jefferson@bch.n-i.nhs.uk
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